Completed PHASE4 INTERVENTIONAL 3-arm NCT00415701

Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery

Effect of an Anesthetic Induction Dose of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery

Sponsor: Insel Gruppe AG, University Hospital Bern

Conditions Coronary Artery Disease Mitral Valve Regurgitation

Interventions Etomidate Hydrocortisone NaCl 0.9% Propofol Tetracosactin

Updated 7 times since 2017 Last updated: Mar 3, 2010 Started: Nov 30, 2006 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Coronary Artery Disease and Mitral Valve Regurgitation and is currently completed. Insel Gruppe AG, University Hospital Bern leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jul 2023 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2023 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Insel Gruppe AG, University Hospital Bern

Data source: Insel Gruppe AG, University Hospital Bern

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bern, Switzerland